Takii M, Kodama T, Otonari T
Jpn J Antibiot. 1984 May;37(5):802-6.
Netilmicin (NTL), a new semisynthesized aminoglycoside, was evaluated in 11 episodes of infection in 10 patients, who had severe underlying diseases, such as acute myocardial infarction, cerebral infarction, malignancy and hepatic cirrhosis. The infection was bacteremia in 3 cases, urinary tract infections in 3 cases and respiratory tract infections in 5 cases. NTL was administered intramuscularly at a dose of 100 mg twice a day for 3 to 14 days. Overall clinical efficacy was only 40%, including excellent in 2 cases, good in 2 cases, fair in 3 cases and poor in 3 cases. Bacteriologically, 2 episodes of E. coli, 2 of S. marcescens and 1 of K. pneumoniae were eradicated, whereas, 2 of P. aeruginosa were decreased, and 1 of K. pneumoniae and 1 of P. rettgeri were persisted. Transient eosinophilia was observed in 1 case, and also nephrotoxicity was encountered in 1 case.
奈替米星（NTL）是一种新的半合成氨基糖苷类抗生素，对10例患有严重基础疾病（如急性心肌梗死、脑梗死、恶性肿瘤和肝硬化）的患者的11次感染进行了评估。感染类型为3例菌血症、3例尿路感染和5例呼吸道感染。奈替米星通过肌肉注射给药，剂量为100mg，每日两次，疗程为3至14天。总体临床疗效仅为40%，其中2例为优，2例为良，3例为中，3例为差。细菌学方面，2例大肠杆菌感染、2例粘质沙雷氏菌感染和1例肺炎克雷伯菌感染被根除，而2例铜绿假单胞菌感染有所减少，1例肺炎克雷伯菌感染和1例雷氏普罗威登斯菌感染持续存在。1例出现短暂性嗜酸性粒细胞增多，1例出现肾毒性。
